BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15152500)

  • 1. [Mechanisms to control degradation of polyglutamine-containing protein].
    Nakayama K
    Rinsho Shinkeigaku; 2003 Nov; 43(11):906-8. PubMed ID: 15152500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurodegenerative diseases regulated by ubiquitin-proteasome system].
    Hatakeyama S
    Rinsho Shinkeigaku; 2006 Nov; 46(11):890-2. PubMed ID: 17432211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
    Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular clearance of ataxin-3 is regulated by a mammalian E4.
    Matsumoto M; Yada M; Hatakeyama S; Ishimoto H; Tanimura T; Tsuji S; Kakizuka A; Kitagawa M; Nakayama KI
    EMBO J; 2004 Feb; 23(3):659-69. PubMed ID: 14749733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit.
    Cemal CK; Carroll CJ; Lawrence L; Lowrie MB; Ruddle P; Al-Mahdawi S; King RH; Pook MA; Huxley C; Chamberlain S
    Hum Mol Genet; 2002 May; 11(9):1075-94. PubMed ID: 11978767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of expanded polyglutamine protein induces behavioral changes in Drosophila (polyglutamine-induced changes in Drosophila).
    Kim YT; Shin SM; Lee WY; Kim GM; Jin DK
    Cell Mol Neurobiol; 2004 Feb; 24(1):109-22. PubMed ID: 15049515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
    Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD.
    Jana NR; Nukina N
    Neurotox Res; 2004; 6(7-8):523-33. PubMed ID: 15639784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis.
    Doss-Pepe EW; Stenroos ES; Johnson WG; Madura K
    Mol Cell Biol; 2003 Sep; 23(18):6469-83. PubMed ID: 12944474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
    Jia D; Jiang H; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
    Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
    J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six cases of SCA3/MJD patients that mimic hereditary spastic paraplegia in clinic.
    Wang YG; Du J; Wang JL; Chen J; Chen C; Luo YY; Xiao ZQ; Jiang H; Yan XX; Xia K; Pan Q; Tang BS; Shen L
    J Neurol Sci; 2009 Oct; 285(1-2):121-4. PubMed ID: 19608203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p45, an ATPase subunit of the 19S proteasome, targets the polyglutamine disease protein ataxin-3 to the proteasome.
    Wang H; Jia N; Fei E; Wang Z; Liu C; Zhang T; Fan J; Wu M; Chen L; Nukina N; Zhou J; Wang G
    J Neurochem; 2007 Jun; 101(6):1651-61. PubMed ID: 17302910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism.
    Warrick JM; Morabito LM; Bilen J; Gordesky-Gold B; Faust LZ; Paulson HL; Bonini NM
    Mol Cell; 2005 Apr; 18(1):37-48. PubMed ID: 15808507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals.
    Nishiyama K; Murayama S; Goto J; Watanabe M; Hashida H; Katayama S; Nomura Y; Nakamura S; Kanazawa I
    Ann Neurol; 1996 Nov; 40(5):776-81. PubMed ID: 8957019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse.
    Wang HL; Hu SH; Chou AH; Wang SS; Weng YH; Yeh TH
    Neuropharmacology; 2013 Jul; 70():1-11. PubMed ID: 23347954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates.
    Zhong X; Pittman RN
    Hum Mol Genet; 2006 Aug; 15(16):2409-20. PubMed ID: 16822850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
    Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP
    Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.